Bone fracture

OrthoInfo.org Offers Osteoporosis Awareness and Prevention Resources for Patients

Retrieved on: 
Mercoledì, Maggio 1, 2024
American Academy, Bone fracture, Patient, Interview, Risk, Fracture, Osteoporosis, Exercise, Diet, AAOS, Ageing, Bone density, Organization, Smoke, Dietary supplement

ROSEMONT, Ill., May 1, 2024 /PRNewswire/ -- This May, OrthoInfo.org, the authoritative and trusted source on bone and joint health, is joining organizations across the country to raise awareness about prevention strategies that can help reduce one's risk of developing osteoporosis. From articles about bone health basics to osteoporosis prevention and treatment options, OrthoInfo offers a variety of resources carefully developed and reviewed by experts from the American Academy of Orthopaedic Surgeons (AAOS) to help patients guide bone health decisions as a lifelong commitment.

Key Points: 
  • From articles about bone health basics to osteoporosis prevention and treatment options, OrthoInfo offers a variety of resources carefully developed and reviewed by experts from the American Academy of Orthopaedic Surgeons (AAOS) to help patients guide bone health decisions as a lifelong commitment.
  • "Osteoporosis can be a debilitating bone disease that occurs when the body loses too much bone, makes too little bone, or both.
  • "By familiarizing yourself with the controllable risk factors, such as diet, exercise and lifestyle choices, patients can better navigate the complex process of managing osteoporosis."
  • Orthopaedic surgeons are the front line of recognizing patients with osteoporosis and those at high risk of osteoporosis-related fractures.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Martedì, Marzo 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Bone Health and Osteoporosis Foundation Applauds President's Executive Order Directing Bold Action to Improve Care for Those With Osteoporosis

Retrieved on: 
Giovedì, Marzo 21, 2024
Milliman, Bone fracture, Bone health, First lady, Osteoporosis, White, Patient, Nursing, Fracture, Executive order, Research, HHS, Policy, Splenic infarction, Ageing, Laboratory, Stroke, Woman, Breast cancer, Medicare, Government, Federation, Dietary supplement

ARLINGTON, Va., March 21, 2024 /PRNewswire/ -- Earlier this week, President Biden issued a sweeping Executive Order directing Federal government agencies to take bold actions to improve women's health research and to assure that the "gains made in research laboratories are translated into real-world clinical benefits for women." In his published statement accompanying the Executive Order, the President specifically highlighted osteoporosis as a critical women's health condition that was being targeted for action. 

Key Points: 
  • In his published statement accompanying the Executive Order , the President specifically highlighted osteoporosis as a critical women's health condition that was being targeted for action.
  • Specifically, the White House statement says that the President is directing the Department of Health and Human Services (HHS) to "identify ways to improve … the clinical care that women receive" for diseases and conditions such as osteoporosis.
  • "This is a major victory for the 10 million Americans with osteoporosis," said Claire Gill, CEO of the Bone Health and Osteoporosis Foundation.
  • "We're grateful to President Biden and the First Lady for recognizing the need for action to help those with osteoporosis.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Venerdì, Marzo 8, 2024
OXM, Woman, Injection, Research, Bone fracture, Clinical research associate, Type D, FDA, BMD, PTH, Food, Hypoparathyroidism, Obesity, Coeliac disease, Weight loss, Oxyntomodulin, Cmax, Elective surgery, Sport, Short bowel syndrome, OPKO Health, DSM-IV codes, Ecosystem, SABRE, Patient, D&O, Intellectual property, Fracture, Athlete, Sports medicine, Tablet, Osteoporosis, Insurance

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

Sandoz receives FDA approval for first and only denosumab biosimilars

Retrieved on: 
Martedì, Marzo 5, 2024
Bone fracture, Fracture, Woman, Hypocalcemia, Osteoporosis, Bone disease, Hypercalcaemia, FDA, Quality of life, Food, Cancer, Denosumab, Metastasis, Risk, Breast, Safety, Mitigation, Novartis, REMS, Benign tumor, Disease, Patent, Patient, Medicine, Multiple myeloma, Ageing, Dietary supplement

Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients.

Key Points: 
  • Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients.
  • I am proud that Sandoz continues to pioneer access to these life-changing medicines for the patients who need them most."
  • Wyost® and Jubbonti® have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines.
  • Given ongoing patent litigation around these products, Sandoz will not comment on anticipated launch timing or other launch details at this time.

J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors

Retrieved on: 
Martedì, Marzo 5, 2024
Medical Devices, Health, Surgery, Other Health, General Health, Biotechnology, Acquisition, Champaign–Urbana metropolitan area, Bone fracture, Enovis, Mechanical, Foot, Doctor of Philosophy, Pelvis, NuVasive, University, Mechanical engineering, Patient, Anatomy, Science, Trauma, Research, Nursing

CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.

Key Points: 
  • CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.
  • “We are delighted to welcome Kurt to CurvaFix’s Board of Directors,” said Mark Foster, CEO at CurvaFix.
  • “His extensive experience and proven track record of success in the orthopedic medical device sector makes him an invaluable addition to our board.
  • “I am honored to join CurvaFix’s excellent Board of Directors,” said Dr. Jacobus.

ConcertAI's TeraRecon Launches Three New Care Suites, Life Sciences Platform, and Strategic Partnerships at #ECR24

Retrieved on: 
Lunedì, Febbraio 26, 2024
MRI, CE, Algorithm, Radiology, Doctor of Philosophy, AI, Research, Gen, Intuition, Extrapyramidal system, FDA, Cardiology, Generative, Integration, Workflow, Bone fracture, Synthetic media, ECR, Software as a service, KLAS, Pancreatic duct, Genomics, Multi, Prostate cancer, Medical imaging

CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- ConcertAI's TeraRecon, the #1 KLAS-ranked advanced visualization and AI Clinical SaaS solution, has announced that European healthcare providers now have access to its cardiology, pulmonology, and neurology suites. In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum. TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.

Key Points: 
  • In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum.
  • TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.
  • Outside the show floor, TeraRecon and Perspectum will present an AI Lightning Talk, titled Integrating AI in Clinical Care on Friday March 1st @ 12:50PM.
  • This first-in-class platform seamlessly integrates Intuition advanced visualization, TeraRecon clinical AI imaging solutions, digital pathology, genomics, and electronic medical record derived clinical data.

ConcertAI's TeraRecon Launches Three New Care Suites, Life Sciences Platform, and Strategic Partnerships at #ECR24

Retrieved on: 
Lunedì, Febbraio 26, 2024
MRI, CE, Algorithm, Radiology, Doctor of Philosophy, AI, Research, Gen, Intuition, Extrapyramidal system, FDA, Cardiology, Generative, Integration, Workflow, Bone fracture, Synthetic media, ECR, Software as a service, KLAS, Pancreatic duct, Genomics, Multi, Prostate cancer, Medical imaging

CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- ConcertAI's TeraRecon, the #1 KLAS-ranked advanced visualization and AI Clinical SaaS solution, has announced that European healthcare providers now have access to its cardiology, pulmonology, and neurology suites. In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum. TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.

Key Points: 
  • In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum.
  • TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.
  • Outside the show floor, TeraRecon and Perspectum will present an AI Lightning Talk, titled Integrating AI in Clinical Care on Friday March 1st @ 12:50PM.
  • This first-in-class platform seamlessly integrates Intuition advanced visualization, TeraRecon clinical AI imaging solutions, digital pathology, genomics, and electronic medical record derived clinical data.

Rep. Kat Cammack Named Winner of 2023 Bone Health Champion Award

Retrieved on: 
Martedì, Gennaio 16, 2024
Caucus, Woman, Bone density, Bone fracture, Osteoporosis, Health, Life, Fracture, Medicare, Stroke, Breast cancer, Risk, Disease, Congress, Bone health, Congressional caucus, Pharmaceutical industry

ARLINGTON, Va., Jan. 16, 2024 /PRNewswire/ -- The Bone Health and Osteoporosis Foundation (BHOF) is pleased to announce that Rep. Kat Cammack (R-FL) has been selected to receive the 2023 Congressional Bone Health Champion Award.

Key Points: 
  • ARLINGTON, Va., Jan. 16, 2024 /PRNewswire/ -- The Bone Health and Osteoporosis Foundation (BHOF) is pleased to announce that Rep. Kat Cammack (R-FL) has been selected to receive the 2023 Congressional Bone Health Champion Award.
  • Rep. Cammack joined with the Caucus and the Bone Health and Osteoporosis Foundation in sponsoring a congressional briefing on women's bone health throughout the lifetime.
  • "The importance of bone health and its impact on an individual's overall health as well as healthcare costs is often overlooked by policymakers," said Claire Gill, CEO of the Bone Health and Osteoporosis Foundation.
  • Rep. Cammack said, "It's an honor to be named one of this year's Congressional Bone Health Champion Award recipients.

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
Martedì, Gennaio 2, 2024
Patient, Urine, Medical Subject Headings, Marketing, INN, Risk, Fracture, Alkaline phosphatase, Woman, Allergy, Heart rate, Vitamin D, ATC, Hypercalcaemia, Menopause, International, Diet, Parathyroid hormone, Headache, Disease, Osteosarcoma, Nausea, Blood, Language, Calcium, Osteoblast, Palpitations, Cancer, Heart, Dizziness, Abdomen, European Medicines Agency, Spine, Back pain, Hypercalciuria, Select, System, Safety, Cardiovascular disease, Anatomy, Arthralgia, Bone fracture, Female, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised